Migraine, CGRP drug and Botox denials in California external review
This evidence graph contains 993 distinct California DMHC review decisions that named migraine, a CGRP treatment, or Botox/onabotulinum. Reviewers overturned the plan in 60.2% of that historical graph. It is a discovery cohort, not a forecast and not a purely migraine-only denominator.
SOURCE: CA DMHC INDEPENDENT MEDICAL REVIEW DATA · DISTINCT REFERENCE-ID UNION · METHOD & LIMITS
The 993-decision graph joins overlapping condition and treatment nodes and counts each decision once. The 754-decision diagnosis cohort is the cleaner migraine-only view. Botox is also used for non-migraine conditions, so its treatment node and the complete graph must not be represented as migraine-only outcomes.
The named-treatment record
These rows are independently deduplicated named-treatment nodes. A decision can name more than one treatment, so the rows overlap and do not add to 993. Rates below the site’s 12-decision publication floor are not shown.
| Treatment | Role | Decisions | Overturned |
|---|---|---|---|
| Ajovy (fremanezumab) | CGRP preventive antibody | 18 | 88.9% |
| Emgality (galcanezumab) | CGRP preventive antibody | 29 | 79.3% |
| Aimovig (erenumab) | CGRP preventive antibody | 36 | 72.2% |
| Nurtec ODT (rimegepant) | Acute and preventive gepant | 38 | 86.8% |
| Qulipta (atogepant) | Preventive gepant | 21 | 90.5% |
| Ubrelvy (ubrogepant) | Acute gepant | 18 | 94.4% |
| Botox (onabotulinumtoxinA) | Chronic-migraine prevention; node includes other indications | 526 | 58.7% |
CGRP prevention, acute gepants and Botox are different lanes
The appeal should identify what the treatment is being used for. Ajovy, Emgality, Aimovig and Vyepti are preventive CGRP-targeting antibodies. Qulipta is preventive; Nurtec ODT has acute and preventive uses; Ubrelvy and Zavzpret are acute treatments. Botox’s adult chronic-migraine indication has a different frequency threshold and administration model. Do not let a plan evaluate one lane under the criteria for another.
A 2024 American Headache Society position statement says CGRP-targeting therapies should be considered first-line preventive options without a blanket requirement to fail older classes first. That is current clinical guidance, not a law forcing every plan to cover every drug. The applicable FDA identity and indication still matter: see the current Ajovy label, Emgality label, and FDA Botox chronic-migraine review.
Why plans deny migraine treatment
Step therapy or a preferred product
The plan wants an older preventive or a different CGRP product first. The record should state each prior trial, dose, duration, response, adverse effect, contraindication, and the requested exception.
Episodic-versus-chronic documentation
A missing headache diary can leave the reviewer unable to verify monthly headache days, monthly migraine days, typical duration, and the chronic-migraine threshold relevant to Botox.
Continuation or reauthorization
Plans may ask for measurable benefit. Document the before-and-after frequency, severity, acute-medication use, disability, emergency care, and what happened during any lapse.
Combination therapy
A plan may treat Botox plus a CGRP preventive as duplicative. The prescriber should explain the residual burden on monotherapy, contribution of each treatment, and why stopping one is clinically inappropriate.
Quantity, refill or site-of-care rules
Pharmacy quantity limits affect self-administered drugs; Botox and infused Vyepti can trigger medical-benefit, buy-and-bill, network, or site-of-care rules. Identify which benefit and rule produced the denial.
Age or indication mismatch
Pediatric and off-label requests require an evidence record that is different from an on-label adult request. Do not describe a use as FDA-approved unless the current label actually says so.
Does “detox” help migraine?
If “detox” meant Botox, Botox is an established prescription treatment for prevention of chronic migraine in the FDA-defined adult population. If detox meant a cleanse, that is not an established migraine treatment. The medically recognized issue is medication-overuse headache: frequent use of some acute headache medicines can perpetuate headache, and a clinician may recommend withdrawal of the overused medicine together with a prevention plan.
Withdrawal should be individualized. The American Headache Society’s medication-overuse guide explains that some medicines are stopped abruptly while opioids, butalbital and high-caffeine products may require tapering or a higher level of support. In one randomized trial, adding botulinum toxin A did not improve outcomes beyond acute withdrawal for chronic migraine with medication overuse; see the trial record. This is not a reason to stop a medicine without the prescribing clinician. Substance-use withdrawal is a separate safety issue; see the behavioral-health level-of-care guide.
Build the appeal record before arguing the medicine
- The complete denial notice and the exact medical-necessity, step-therapy, formulary, quantity, and site-of-care criteria used.
- A headache diary showing monthly headache days, monthly migraine days, usual duration, severity, associated symptoms, and acute-medication use.
- Every preventive and acute treatment tried: dose, dates, duration, response, adverse effect, and reason it was stopped or cannot be used.
- For continuation: baseline versus current frequency, disability, missed work or school, emergency care, and rescue-medication use.
- For Botox: the diagnosis, injection cycle, prior response, and the clinician's basis for chronic rather than episodic migraine.
- A neurologist or treating clinician letter that answers the plan's criteria point by point and states the current FDA indication accurately.
Explore the underlying evidence: migraine decisions · chronic-migraine decisions · prescription-drug denials · prior authorization · appeal rights by plan type.
Migraine denial FAQ
Common issues include a plan-preferred drug, step therapy, missing documentation of monthly migraine days or prior preventive trials, refill timing, and a diagnosis or age that does not match the plan's criteria. The appeal should answer the exact reason in the denial notice and attach the plan criteria, headache history, prior-treatment log, and prescriber rationale.
Yes. For an on-label adult chronic-migraine request, document headache-day frequency, typical duration, prior preventive treatments, and the requested injection cycle. If Botox previously worked, include the response and what happened when treatment was delayed. Coverage rules and appeal deadlines still depend on the plan.
Some plans impose step therapy. A 2024 American Headache Society position statement supports CGRP-targeting therapies as first-line preventive options, but that clinical position is not itself a binding coverage rule. Use it with the patient's record, FDA indication, plan language, and any applicable exception right.
A general detox or cleanse is not an established migraine treatment. A different issue, medication-overuse headache, may be treated with clinician-supervised withdrawal of the overused acute medication and a prevention plan. Some medicines require tapering, so a patient should not abruptly stop opioids, butalbital, benzodiazepines, or other dependence-forming drugs without medical guidance.
Combination requests are often reviewed under plan-specific criteria. The prescriber should explain the remaining disability on one therapy, response attributable to each treatment, why stopping either would be harmful, and the evidence supporting combination care. The FDA label and a plan's coverage policy are different documents.
They are a deduplicated California DMHC discovery graph: a decision is included if an extracted condition names migraine or an extracted treatment names a covered CGRP drug or Botox/onabotulinum. Botox has non-migraine uses, so 993 is not a migraine-only denominator. The narrower diagnosis cohort contains 754 decisions.
DATA: CA DMHC SOURCE CSV · SNAPSHOT 2026-07-31 · CLINICAL SOURCES REVIEWED 2026-08-25 · FULL METHODOLOGY